Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

BACKGROUND: HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib. The aim of HERACLES-B trial is to assess the efficacy of the combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartore-Bianchi, Andrea, Lonardi, Sara, Martino, Cosimo, Fenocchio, Elisabetta, Tosi, Federica, Ghezzi, Silvia, Leone, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Ciardiello, Fortunato, Ardizzoni, Andrea, Amatu, Alessio, Bencardino, Katia, Valtorta, Emanuele, Grassi, Elena, Torri, Valter, Bonoldi, Emanuela, Sapino, Anna, Vanzulli, Angelo, Regge, Daniele, Cappello, Giovanni, Bardelli, Alberto, Trusolino, Livio, Marsoni, Silvia, Siena, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523198/
https://www.ncbi.nlm.nih.gov/pubmed/32988996
http://dx.doi.org/10.1136/esmoopen-2020-000911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523198/
https://www.ncbi.nlm.nih.gov/pubmed/32988996
http://dx.doi.org/10.1136/esmoopen-2020-000911

Ejemplares similares